预约演示

更新于：2026-01-14

Cetirizine Hydrochloride

盐酸西替利嗪

更新于：2026-01-14

概要

基本信息

简介盐酸西替利嗪是一种小分子药物，通过作为H1受体拮抗剂来靶向H1受体。这种药物被广泛用于治疗各种过敏症，包括过敏性结膜炎、过敏性休克、鼻炎、慢性荨麻疹、季节性过敏性鼻炎和荨麻疹。盐酸西替利嗪由强生公司研制，于1991年首次获批用于医疗。通过阻止H1受体，该药物有助于防止组胺的结合，组胺是引起许多过敏反应症状的罪魁祸首。虽然该药物通常耐受良好，但一些患者可能会出现嗜睡或口干等副作用。总的来说，盐酸西替利嗪仍然是治疗各种过敏症的高效药物。

药物类型

小分子化药

别名

Cetirizien Hydrochloride Drops、Cetirizine、Cetirizine Dihydrochloride

+ [47]

靶点

H1 receptor

作用方式

拮抗剂

作用机制

H1 receptor拮抗剂(组胺H1受体拮抗剂)

治疗领域

免疫系统疾病感染眼部疾病+ [3]

在研适应症

季节性过敏性鼻炎变应性结膜炎皮炎+ [8]

非在研适应症

急性结膜炎慢性荨麻疹特应性皮炎+ [2]

原研机构

Johnson & Johnson

在研机构

UCB Japan Co. Ltd.Teva UK Ltd.

AFT Pharmaceuticals Ltd.

+ [7]

非在研机构

GSK PlcJohnson & Johnson de Colombia SA

McNeil AB

+ [7]

权益机构

Apotex, Inc.ITROM Pharmaceutical Group

Santen Pharmaceutical Co., Ltd.

+ [14]

最高研发阶段批准上市

首次获批日期

加拿大 (1991-12-31),

过敏性鼻炎荨麻疹

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C21H26Cl2N2O3

InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N

CAS号83881-52-1

关联

145

项与盐酸西替利嗪相关的临床试验

NCT07236372

/ Not yet recruitingN/AIIT

Comparative Efficacy of Standard-Dose Versus Updosed Cetirizine in Acute Urticaria: A Randomized Controlled Trial

The goal of this clinical trial is to learn whether a higher dose of cetirizine works better than the standard dose to relieve symptoms of acute urticaria (hives) in adults. The study also aims to learn about the safety of taking a higher dose for a short period of time.
The main questions the study aims to answer are:
Does the higher dose of cetirizine help people with acute urticaria improve faster than the standard dose? What side effects do participants experience when taking the higher dose?
Researchers will compare two groups:
one group taking the standard dose of cetirizine (10 mg per day) and another group taking a higher dose (40 mg per day). This will help researchers understand which dose works better and whether the higher dose is safe.
Participants will:
Take the assigned study medication for 7 days Record their daily symptoms, including itch and hive severity Return for follow-up visits on Day 3, Day 7, and Week 6 Have blood tests to check liver and kidney function before and after treatment
This study may help improve treatment options for people with acute urticaria and reduce the need for unnecessary steroid use.

开始日期2025-11-01

申办/合作机构

University of Phayao

CTRI/2025/09/095267

/ Not yet recruiting临床2期IIT

Evaluation of comparative efficacy of Champakadi Agada versus Cetirizine in Sheetapitta (Recurrent Urticaria)-A reverse pharmacology approach. - nil

开始日期2025-10-05

申办/合作机构-

IRCT20130626013776N119

/ SuspendedN/A

A study to compare the relative bioavailability of Loghman and GlaxoSmithKline formulations of cetirizine 10 mg tablets in 24 healthy adult volunteers under fasting conditions

开始日期2025-08-23

申办/合作机构-

100 项与盐酸西替利嗪相关的临床结果

登录后查看更多信息

100 项与盐酸西替利嗪相关的转化医学

登录后查看更多信息

100 项与盐酸西替利嗪相关的专利（医药）

登录后查看更多信息

2,746

项与盐酸西替利嗪相关的文献（医药）

2026-01-01·FORENSIC SCIENCE INTERNATIONAL

Postmortem distribution of isotonitazene and its three metabolites in the first lethal case observed in France

Article

作者: Eiden, C ; Peyriere, H ; Martrille, L ; Mathieu, O ; Lossois, M ; Bendjilali-Sabiani, J-J

BACKGROUND:

Isotonitazene (IZN) is a potent synthetic opioid associated with a growing number of fatal intoxications worldwide. Despite its increasing presence in forensic cases, postmortem data regarding the distribution of IZN and its metabolites in human tissues remain limited.

CASE PRESENTATION:

We report the first documented case of fatal IZN intoxication in France, involving a 39-year-old man with a history of heroin use. Comprehensive postmortem toxicological analysis was conducted using a LC-MS/MS quantification method. Quantification of IZN and its three active metabolites: N-desethyl-isotonitazene, 4'hydroxy-nitazene, and 5-amino-isotonitazene was performed in multiple matrices, including blood, urine, bile, and solid organs.

RESULTS:

IZN was detected in femoral and cardiac blood, with concentrations of 1.20 ng/mL and 1.74 ng/mL, respectively. High concentrations were observed in the heart (20 ng/g), lungs (32.6 ng/g), and brain (7.9 ng/g), consistent with marked postmortem redistribution. Active metabolites showed variable distribution: N-desethyl isotonitazene was detected in lung tissue and brain, 5-amino isotonitazene in both brain and lungs, while 4'-hydroxy-nitazene appeared to be predominantly eliminated via the biliary route. A high concentration of IZN at the injection site (343.2 ng/mL) indicated intravenous administration. Ethanol and cetirizine were also present at non-lethal concentrations.

CONCLUSION:

To the best of our knowledge, this is the first reported fatal IZN intoxication with comprehensive postmortem analysis, including quantification of active metabolites in solid organs. The case is marked by low peripheral blood levels, extensive redistribution, and selective tissue accumulation. Active metabolites: N-desethyl IZN, 4'-hydroxy-nitazene, and 5-amino IZN showed distinct distribution and elimination profiles. These findings highlight the high potency, rapid metabolism, and complex toxicokinetic of IZN.

2026-01-01·Eye & Contact Lens-Science and Clinical Practice

Long-Term Monitoring of an Intracorneal Bee Stinger Using Anterior Segment Optical Coherence Tomography and In Vivo Confocal Microscopy

Article

作者: Bozkurt, Banu ; Oflaz, Ayşe Bozkurt ; Huseynli, Nicat ; Evren Kemer, Özlem

Abstract::

A 19-year-old male patient presented to our clinic with complaints of foreign-body sensation, pain, redness, tearing, and decreased vision in the right eye. One day prior, a bee struck his eye while he was riding a motorcycle. Biomicroscopic examination of the right eye showed periorbital edema, chemosis, ciliary injection, corneal edema with radiating Descemet folds, paracentral corneal infiltrate, and a brown needle-like foreign body resembling a bee stinger. Anterior segment optical coherence tomography (AS-OCT) confirmed corneal edema with Descemet folds, whereas in vivo confocal microscopy (IVCM) revealed multiple hyporeflective, round cyst-like structures within the superficial corneal epithelium, hyperreflective, round inflammatory cells around the subbasal nerves, a honeycomb pattern, and a hyperreflective, needle-like linear opacity in the stroma. The patient was treated with topical moxifloxacin 0.5%, dexamethasone 0.1%, and fluconazole 0.2% eye drops and oral moxifloxacin (400 mg) and cetirizine (10 mg) tablets. The patient's signs and symptoms improved significantly within 1 week. At the 18-month examination, the patient's vision was 20/20, with only a faint stromal opacity remaining. No stinger fragments were detected on biomicroscopic examination, AS-OCT, or IVCM examination. Anterior segment optical coherence tomography and IVCM are highly valuable for monitoring corneal edema, inflammation, cellular changes, and the embedded stinger within the cornea throughout the follow-up period.

2026-01-01·JOURNAL OF DERMATOLOGY

Minocycline‐Induced Delayed Dermographism With Tolerance to Doxycycline

Article

作者: Muñoz‐Díaz, Egleé Elena ; Dávila, Ignacio ; Lázaro‐Sastre, Milagros ; Cabrera‐Núñez, Adelaida ; Laffond‐Yges, Elena ; Muñoz‐Bellido, Francisco Javier ; Mazoteras‐Martínez, Elena ; Otero‐Fernández, María Nerea

ABSTRACT:

Minocycline, a semisynthetic tetracycline, is widely used to treat inflammatory skin diseases such as acne and rosacea. Despite its favorable safety profile, it may cause various adverse effects, including hypersensitivity reactions. We describe the case of a 20‐year‐old male who developed delayed‐onset symptomatic dermographism following oral minocycline treatment (100 mg/day) for acne. One week after starting treatment, the patient developed pruritic, evanescent, linear wheal‐like lesions at multiple sites, without angioedema or systemic symptoms. Lesions resolved spontaneously within two weeks of drug withdrawal. An oral challenge test with escalating doses of minocycline, up to a cumulative total of 100 mg initially, showed tolerance; however, symptoms recurred after nine consecutive days at the therapeutic dose, confirming causality. Symptoms resolved following drug discontinuation and a 2‐day course of oral cetirizine. To evaluate cross‐reactivity, prick and intradermal tests with doxycycline were negative, and a 10‐day oral doxycycline challenge was uneventful, indicating no cross‐reactivity. Symptomatic dermographism is the most common form of chronic inducible urticaria, but its association with minocycline is rare. The underlying immunopathogenesis remains unclear, potentially involving mast cell activation or superantigen‐like effects. This case underscores the importance of prolonged drug rechallenge in identifying rare delayed adverse reactions such as minocycline‐induced late‐onset symptomatic dermographism and supports the safe use of doxycycline as an alternative.

405

项与盐酸西替利嗪相关的新闻（医药）

2026-01-13

·smo随访专家

特应性皮炎用药指南：规范用药，守护健康肌肤

特应性皮炎（AD）也常被叫做 “异位性皮炎”或“特应性湿疹”，是一种常见的慢性、复发性、炎症性皮肤病，表现为湿疹样皮疹、皮肤干燥，且伴有剧烈的痒感，严重影响生活质量。 AD是一种慢性病，需要长期治疗和管理。规范用药是控制瘙痒及减少复发的关键。本文将结合临床常用方案，为您讲清各类药物的具体用法、注意事项和常见问题，帮您安全用好每一种药。 01 外用药物外用药物是AD最常用的治疗方法，需根据皮损部位及严重程度等因素选对药、用对药。 1.外用糖皮质激素（TCS）适用情况： TCS是治疗轻中度AD的一线药物，合理使用可迅速控制病情，减轻炎症和瘙痒。如何选药：医生会按AD的部位匹配强度（越轻的皮损、越薄嫩的部位，（如面部、眼周、皮肤褶皱处，选越弱的药），常见分类如下：强度代表药物弱效氢化可的松、地奈德等中效糠酸莫米松、曲安奈德、丁酸氢化可的松等强效哈西奈德等超强效卤米松、丙酸氯倍他索等正确用法：用量：遵循“指尖单位”原则（1个指尖单位=从食指尖到第一指间关节的药膏量，可涂2个手掌大小的皮损），薄薄涂一层即可，无需反复涂抹。顺序：与保湿剂间隔15~30分钟。若用的是软膏剂型的TCS，可先涂保湿剂，吸收后再涂TCS（以避免软膏基质影响保湿剂的渗透）。疗程：超强效和强效激素连用不超过2 ~ 3周，中效激素连用不超过4 ~ 6周。皮肤薄嫩部位酌情缩短疗程。需遵医嘱使用足够强度、足够疗程，好转后再换成中弱效激素或非激素类药膏或减少药膏使用的频率。建议在急性期症状缓解后进行“主动维持治疗”—— 每周涂2 次，减少复发。注意事项：皮肤柔嫩部位（面颈部、眼周、腋窝、腹股沟、会阴等）首选弱效或中效激素，慎用强效和超强效激素；儿童用药优先选弱效激素。长期连续使用可能导致皮肤变薄、毛细血管扩张、痤疮或毛囊炎等，请按医嘱用药，若出现这些情况请您及时告知医生。 2.钙调神经磷酸酶抑制剂（TCI）适用情况：面颈部、乳房、肛门外生殖器等薄嫩部位，或用于长期维持治疗（替代激素，避免激素副作用）。代表药物： 1%吡美莫司乳膏（轻中度AD）、0.1% 他克莫司软膏（成人中重度 AD）和0.03% 他克莫司软膏（2岁以上儿童）。正确用法： 1、建议每日外用2次，直至皮损消退或遵医嘱，然后采用主动维持治疗（每周2 d，每日1次），可以减少AD复发，延长复发间期。 2、初期若有灼烧感、刺痛感，可先把药膏放冰箱冷藏10分钟再用，或先涂保湿剂，间隔 15 分钟后再涂TCI，可减轻刺激。 3、若刺激感一周无好转或急性期皮损刺激症状明显，可先用TCS控制急性症状，再换成TCI维持。注意事项：长期用不会导致皮肤萎缩，但需注意防晒（少数人用药后皮肤会光敏感）。 3.PDE-4抑制剂适用情况： 2岁及以上儿童和成人的轻中度 AD，无部位限制。用于长期维持治疗（替代外用激素，避免激素副作用）。代表药物：2% 克立硼罗软膏正确用法： 1、每日2次，直接涂于皮损处，初始可与TCS联用（比如用TCS的间歇期用），皮肤症状好转后，再单用该药维持治疗。 2、用药部位可能会有灼痛或刺痛感，大多可自行缓解，使用前冷敷可减轻不适感。注意事项：避免用于皮肤破损、溃疡、感染及黏膜处。 4.芳香烃受体调节剂代表药物：1%本维莫得乳膏 1%本维莫德乳膏是一种非激素、小分子免疫调节剂，可通过激活芳香烃受体信号通路，抑制炎症反应，促进皮肤屏障修复。该药已获批准用于治疗2岁及以上AD患者的治疗。国内外临床试验表明其疗效显著。常见的不良反应包括毛囊炎、接触性皮炎、用药部位瘙痒或疼痛等，多为一过性、轻中度，可自行好转。 02 口服/注射药物当外用药控制不佳时，医生会根据情况加用系统药物，需严格遵医嘱使用，不可自行调整剂量。当病情严重或外用药控制不佳时，医生会根据情况加用系统药物，需严格遵医嘱使用，不可自行调整剂量。 1.生物制剂适用情况：外用药控制不好的6个月及以上儿童和成人中重度AD。代表药物：度普利尤单抗、司普奇拜单抗正确用法：皮下注射，成人初始剂量 600mg，之后每2周300mg；儿童用法用量请参照说明书。注意事项：注射后可能有注射部位轻微红肿、疼痛，少数人会出现结膜炎（眼干、发红）、面颈部红斑，若无缓解及时就医。 2.JAK抑制剂适用情况：病情偏重、其他系统治疗无效的中重度 AD（年龄＜65 岁，无心血管、肿瘤风险）。代表药物：乌帕替尼、阿布昔替尼、艾玛昔替尼正确用法：口服每日 1 次，需遵医嘱调整用药剂量。注意事项： • 用药前需查血常规、肝肾功能、血脂、结核、乙肝 / 丙肝，凝血；用药后 1 个月及每 3 个月需复查化验。 • 可能增加带状疱疹、单纯疱疹的风险，若出现发热、皮肤水疱，立即就医。 3.免疫抑制剂适用情况：常规治疗不易控制的重度AD，用药期间需密切监测不良反应。代表药物及注意事项：、环孢素:起始剂量3～5mg·kg-1·d-1，每日分2次口服，病情控制后逐渐减量至停药。常见不良反应为高血压和肾毒性，用药期间应监测血压和肾功能，治疗前需筛查乙型/丙型肝炎和HIV感染。 4.其他抗组胺药：用于合并过敏性鼻炎、荨麻疹的患者。如氯雷他定、西替利嗪等（第二代抗组胺药，嗜睡副作用轻）。少数人可能有嗜睡、口干，开车或高空作业者建议睡前服用。不建议长期用第一代抗组胺药（如扑尔敏），其嗜睡副作用明显。系统糖皮质激素：仅用于病情严重、其他药物难以控制的急性发作期 AD 患者，建议短期应用，病情好转后及时减量停药，不能长期用。使用期间需监测感染、睡眠障碍、高血压、糖尿病、消化道溃疡、骨质疏松等不良反应。复方甘草酸苷：有抗炎、抗变态反应等类似激素的作用。不良反应可能有血钾低、血压高、水肿、体重增加，或者肌肉疼、乏力，使用过程中要注意监测。 03 用药常见问题解答 1.漏涂了一次药怎么办？想起后尽快补涂，但若快到下一次用药时间，直接跳过漏涂的剂量，按原计划用下一次，不要加倍补涂（可能增加副作用）。 2.涂药后皮肤更痒了，是过敏吗？若只是轻微刺痛、灼热，可能是 TCI或PDE-4抑制剂的初期刺激反应，可按上述方法缓解；若出现红肿、起疹子、瘙痒加剧，可能是过敏，立即停药并就医。 3.保湿剂和药膏哪个更重要？都重要！保湿剂是 “基础护理”，每天需涂2~3次（尤其是洗澡后3分钟内涂，锁住水分）；药膏是 “对症治疗”，需按医嘱用。两者结合才能更好修复皮肤屏障。 4.病情好转后能自行停药吗？ AD 容易复发，病情偏重或反复发展者建议 “主动维持治疗”（如每周2次外用药膏）。自行停药可能导致1~2周内病情反弹，建议遵医嘱逐渐减量或调整方案。 04 重要提醒所有药物均需医生根据你的具体情况开具，不可网购 “偏方药膏” 或借用他人药物（可能含强效激素或不明成分，耽误病情）。用药期间定期复诊，医生会根据皮损变化调整方案，不要凭感觉自行停药或换药。除了用药，日常生活中注意复发加重的诱因、避免接触过敏原（如尘螨、宠物毛）、穿纯棉衣物及保持皮肤湿润，对控制 AD 同样重要。特应性皮炎的管理是一场 “持久战”，规范用药 + 科学护理，才能有效控制症状、减少复发。如果用药过程中有任何疑问，及时复诊和医生沟通，一起守护健康肌肤。【SMO随访专家】目前有多个慢病的临床试验正在招募中，如果有符合的患者，扫描下方二维码咨询报名！注：此项目为临床试验项目，具体开展时间、补助等详情，请以研究中心通知和知情同意书为准，更多项目请关注“smo 随访专家“公众号。

2026-01-13

·贵阳皮肤病专科医院

别再抓了！皮肤科医生紧急提醒：接触性皮炎乱抓，严重可致感染，这3步处理是关键

当你因为皮肤上的一个红疹奇痒无比而反复抓挠时，可能正在无意中激化一场皮肤内部的“免疫战争”。在日常生活中，很多人都有过这样的经历：戴了新项链，脖子一圈就起了边界清晰的红疹；换了新洗面奶，脸颊就开始发红、刺痛。这很可能是“接触性皮炎”在作祟。作为一种常见的皮肤炎症，接触性皮炎可因接触刺激性物质或过敏原而引发。最新研究甚至揭示，那个让你“一时爽”的抓挠动作，可能会加剧炎症，让情况变得更糟。 01 病因机制：皮肤屏障的“攻防战” 接触性皮炎的本质是皮肤与外源性物质接触后发生的炎症反应。它主要分为两大类，机制截然不同：刺激性接触性皮炎：这是最常见的类型，占大多数。它并非过敏，而是皮肤屏障被物理或化学方式直接破坏的结果。强酸、强碱、有机溶剂、反复摩擦，甚至反复接触水或肥皂，都可能像“攻城锤”一样，损坏皮肤最外层的保护层，引发炎症。过敏性接触性皮炎：这是一种由T细胞介导的迟发型过敏反应（IV型超敏反应），属于真正的过敏。其过程像一个“蓄谋已久”的免疫应答。首次接触某些物质（如镍、香料、染发剂）时，免疫系统会“记住”它（致敏阶段）。当再次接触时，便会启动攻击，通常在24至48小时后在接触部位出现皮炎。此外，还有光接触性皮炎，指某些物质仅在皮肤接触紫外线后才引发刺激性（光毒性）或过敏性（光敏性）反应。 02 症状识别：皮损形态里的“线索” 接触性皮炎的症状从轻微到严重不等，但通常都包括瘙痒、红斑和皮疹。仔细观察皮损的形态和分布，往往能找到病因线索：急性期表现：皮肤上出现边界清晰的红斑、水肿，严重时会有丘疹、水疱甚至大疱。如果水疱破裂，会出现糜烂、渗出和结痂。慢性期表现：如果长期反复接触弱刺激物或过敏原，皮损可能转为慢性，表现为皮肤干燥、增厚、苔藓样变和脱屑。关键线索：皮疹的形状和位置是重要的诊断线索。例如，线状条纹常提示接触了藤蔓类植物（如毒藤）；手腕圆形红斑可能对应手表表带；腰带下方的皮疹可能与金属扣过敏有关。美发师、医护人员等特定职业人群，皮疹好发于双手。 03 明确诊断：从问诊到“皮肤侦探” 皮肤科医生通常根据典型的皮疹表现和详细的接触史来诊断。为了明确致敏原，尤其是当过敏原不明或患者经治疗后仍反复发作时，斑贴试验是“金标准”。这种测试就像是皮肤的“过敏原大侦探”，将常见的过敏原贴于背部皮肤，留置48小时后移除，分别在移除时及之后24-72小时观察皮肤反应，以判断对何种物质过敏。需要注意的是，斑贴试验对刺激性接触性皮炎无效。 04 阶梯治疗：从避免接触到精准用药接触性皮炎的治疗遵循清晰的阶梯原则，核心永远是 “避开致病原” 。基础与一线治疗 1. 严格避免接触：这是治疗的根本。识别并避免接触刺激物或过敏原是治愈和预防复发的关键。因职业无法避免者，应做好防护（如戴手套）。 2. 外用糖皮质激素：这是控制炎症的主要药物。根据皮炎严重程度和部位，选择不同强度的药膏。对于轻度病例，非处方的氢化可的松可能有帮助，但更多情况需要医生开具更强效的处方药膏。 3. 对症止痒与护理：口服抗组胺药：如西替利嗪、氯雷他定等，可帮助缓解瘙痒。冷湿敷：用凉水或Burow溶液（醋酸铝）浸湿纱布敷在患处，每次约一小时，每日数次，有助于收敛、干燥渗出的皮损。保湿修复：规律使用无刺激的保湿霜，修复受损的皮肤屏障。系统治疗对于皮疹面积广泛、症状严重（如严重水疱）或外用治疗无效的病例，医生可能会短期（7-14天）使用口服糖皮质激素（如泼尼松）以快速控制严重炎症。前沿治疗进展对于慢性、顽固性或严重影响生活的病例，治疗手段正变得更加丰富：口服PDE-4抑制剂：如罗氟司特，这是一种新型口服抗炎药，通过抑制磷酸二酯酶-4起作用，在研究中显示出对多种炎症性皮肤病的良好疗效。生物制剂与JAK抑制剂：针对特定炎症通路的靶向药物（如用于特应性皮炎的度普利尤单抗）已在临床中用于治疗部分严重的过敏性接触性皮炎。JAK抑制剂这类小分子靶向药的相关临床试验也在进行中。光生物调节疗法（低能量光疗）：2024年的一项基础研究提示，特定波长的低能量光照可能通过调节T细胞功能来抑制过敏性接触性皮炎，为未来物理治疗提供了新思路。 05 预防与管理：生活里的“避雷”指南预防远胜于治疗。以下方法可以帮助您有效规避风险：做个有心人：留意并记录皮疹出现前接触过的所有可疑物品。及时清洗：明确接触刺激物（如毒藤）或过敏原后，立即用温和肥皂和大量清水冲洗接触部位。阅读成分表：购买护肤品、化妆品、清洁剂时养成习惯。替代选择：对镍过敏，选择不锈钢、钛合金或至少18K金的首饰；对橡胶过敏，寻找替代材质的用品。加强防护：从事相关工作或家务时，佩戴合适的防护手套、穿长袖衣物。特别提醒：近期《科学》杂志的一项研究揭示了“瘙痒-抓挠”恶性循环的新机制：抓挠会刺激神经释放P物质，进一步激活肥大细胞，加剧炎症。尽管抓挠可能带来短暂的快感，甚至意外地增强了对某些细菌的防御，但对于皮炎本身，克制抓挠是打破循环、促进愈合的重要一步。接触性皮炎虽常见，但只要准确识别病因、科学规范治疗并坚持有效预防，完全能够控制并避免复发。关键在于，一旦出现症状，切忌乱抓乱用药，应及时咨询皮肤科医生。你是否也有过因接触某些物品而“烂手”或皮肤过敏的经历？后来是如何找到“元凶”并成功解决的呢？欢迎在评论区分享你的故事和经验。每一次理性的回避，都胜过一万次冲动的抓挠。当皮肤亮起红灯，我们需要的不是加重摩擦，而是找出并移开那个看不见的开关。参考文献（上下滑动查看）默沙东诊疗手册. 接触性皮炎（专业版/大众版）[EB/OL]. 2025. Mayo Clinic. Contact dermatitis [EB/OL]. 2025. Zirwas M. “Don’t Touch This”: Contact Dermatitis Insights and Updates [J/OL]. Dermatology Times, 2024. Dickel H, et al. German S1 guideline: Contact dermatitis [J]. JDDG, 2022. Liu AW, et al. Scratching promotes allergic inflammation and host defense via neurogenic mast cell activation [J]. Science, 2025. Fu J, et al. Photobiomodulation suppresses allergic contact dermatitis by inhibiting T‐cell activation [J]. Contact Dermatitis, 2024. *本文内容仅供科普参考，不替代专业医疗建议。具体诊疗请遵皮肤科医生指导。 -END- 本文图片来源于网络，如有侵权请联系删除。本文为科普信息传播，不构成医疗建议。如需专业指导，请至正规医疗机构就诊。

2026-01-13

·PRNewswire

ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence

BARCELONA, Spain and DEERFIELD, Ill., Jan. 13, 2026 /PRNewswire/ -- ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire TerSera's Infusion Specialty Therapies Business Unit (IST). This strategic acquisition enables ESTEVE to expand its U.S. presence, with two highly specialized on-market assets and a dedicated team of sales, marketing and medical professionals. TerSera's IST business unit includes two specialty medications, Prialt® (ziconotide intrathecal infusion) and Quzyttir® (cetirizine hydrochloride injection). Prialt® is the only FDA-approved, non-opioid agent indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine.1 Prialt® is currently marketed in Europe by ESTEVE.2 Quzyttir® is the first and only injectable second-generation H1 antihistamine approved by the FDA for the treatment of acute urticaria in adults and children six months of age and older.3 With this transaction, ESTEVE will obtain worldwide rights for Quzyttir® in all territories (except for China) and consolidates its rights for Prialt® worldwide. Staffan Schüberg, ESTEVE's Chief Executive Officer stated: "We are excited to welcome the Infusion Specialty Therapies Business Unit and look forward to welcoming TerSera's talented team to ESTEVE. This acquisition perfectly aligns with our strategic vision of providing highly specialized solutions where there is a significant unmet medical need. By adding Quzyttir® to our portfolio and expanding to the US market with Prialt®, we not only strengthen our expertise in highly specialized therapies but also accelerate our expansion in the United States—the world's largest pharmaceutical market." "ESTEVE has been our long-term partner for Prialt® in Europe. Their expertise and core areas of focus make them the ideal future owner for IST." said Edward Donovan, Chief Executive Officer of TerSera. "We believe this transaction provides an excellent home for Prialt® and Quzyttir® to continue the strong momentum we have established with these medicines, while we sharpen our focus on our core therapeutic areas of oncology and rare disease." This deal reinforces ESTEVE's growth in the United States, a growth that began with the acquisition in 2024 of a business specialized in rare and ultra-rare diseases in the areas of endocrinology and onco-endocrinology. ESTEVE's highly specialized portfolio has been further strengthened by the subsequent expansion in 2025: licensing-in for Ex US a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency4; an adjuvant treatment being investigated in the U.S. and considered standard of care outside of the U.S. where it is approved for high-grade resectable non-metastatic osteosarcoma in patients aged between 2 and 30 years5 ; and a medicine that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer.6 The current transaction is expected to close in the first quarter of 2026, subject to regulatory clearances. Perella Weinberg Partners are the financial advisor to ESTEVE on this transaction, and Arnold & Porter are serving as legal counsel. Leerink Partners acted as the lead financial advisor to TerSera, and Kirkland & Ellis LLP is serving as legal counsel. About ESTEVE ESTEVE (esteve.com) is a global pharmaceutical company with a clear purpose: to improve people's lives. Founded in 1929 and headquartered in Barcelona, ESTEVE has a strong international presence with pharmaceutical affiliates in Spain, Portugal, Italy, Germany, France, the UK, and the USA.   ESTEVE is focused on delivering highly specialized treatments that address significant unmet medical needs in several therapeutic areas. In addition, to our innovative pharma business, we offer comprehensive Contract Manufacturing and Development services (CDMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, China and the USA. ESTEVE's strong commitment to its core values—people matter, transparency, and accountability—remains at the heart of everything it does. About TerSera Therapeutics TerSera Therapeutics is a biopharmaceutical company with a focus on oncology and rare diseases. Founded in 2016, TerSera is building new cornerstones of care through its portfolio of unique therapeutics, amplifying their ability to deliver meaningful outcomes for patients. TerSera has been recognized as a 2025 Top Workplace. For additional information, please visit TerSera.com and follow us on LinkedIn. For more information: References PRIALT® (ziconotide). Prescribing information. TerSera Therapeutics LLC. Prialt®- QUZYTTIR® (cetirizine hydrochloride injection). Prescribing Information. TerSera Therapeutics LLC. Increlex - Mepact - Caprelsa - Logo - 21% more press release views with Request a Demo

上市批准并购引进/卖出寡核苷酸

100 项与盐酸西替利嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00664	盐酸西替利嗪	R06AE07	DB00341

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
变应性结膜炎	美国	Harrow, Inc.	2017-05-30
皮炎	日本	UCB Japan Co. Ltd.	1998-06-30
湿疹	日本	UCB Japan Co. Ltd.	1998-06-30
瘙痒	日本	UCB Japan Co. Ltd.	1998-06-30
过敏反应	中国	苏州东瑞制药有限公司	1998-01-01
鼻炎	中国	苏州东瑞制药有限公司	1998-01-01
慢性荨麻疹	美国	Johnson & Johnson de Colombia SA	1995-12-08
常年性变应性鼻炎	美国	Johnson & Johnson de Colombia SA	1995-12-08
季节性过敏性鼻炎	美国	Johnson & Johnson de Colombia SA	1995-12-08
过敏性鼻炎	加拿大	Pfizer Canada ULC	1991-12-31
荨麻疹	加拿大	Pfizer Canada ULC	1991-12-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结膜炎	申请上市	韩国	SAMIL PHARMACEUTICAL Co., Ltd.	-
急性荨麻疹	临床3期	美国	JDP Therapeutics LLC	2013-07-01
急性荨麻疹	临床3期	加拿大	JDP Therapeutics LLC	2013-07-01
急性结膜炎	临床3期	美国	Nicox Ophthalmics, Inc.	2012-03-01
特应性皮炎	临床3期	-	GSK Plc	2005-08-01
皮肤真菌病	临床3期	-	GSK Plc	2005-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06019728 (SHORTEN, CTgov)	临床4期	法布里病	8	Fabrazyme	願糧鏇廠鹽襯簾艱鹹夢(餘衊衊築繭窪簾膚鑰選) = 繭壓觸廠構鑰鹹鑰簾襯鑰範積壓築夢觸窪窪膚 (糧窪糧醖鬱鑰積夢觸淵, 築夢夢鹹窪觸獵衊蓋製 ~ 夢簾範衊蓋餘艱構糧壓) 更多	-	2025-10-21
NCT05946551 (CTgov)	临床3期	新冠肺炎后遗症	5	Cetirizine+Famotidine (HRA Treatment Arm)	製鹹廠醖蓋窪遞獵網遞 = 鬱製齋夢鏇遞鹹糧艱壓鹹壓淵願範構糧糧夢鬱 (鏇淵齋獵簾壓範願積積, 餘艱膚製願鑰鏇範淵憲 ~ 鏇衊蓋構夢鑰製鬱遞鏇) 更多	-	2025-07-17
				Famotidine Placebo (Placebo Arm)	製鹹廠醖蓋窪遞獵網遞 = 廠築願齋網簾鑰構鹽範鹹壓淵願範構糧糧夢鬱 (鏇淵齋獵簾壓範願積積, 鬱遞範壓憲繭選製壓膚 ~ 憲艱鹹簾製製鑰壓鏇範) 更多
NCT06039137 (H1-Switch Study, Pubmed \| JCO Oncol Pract)	N/A	-	-	Intravenous Clemastine	鹽繭範鑰餘願觸範壓醖(顧製鑰網鑰鬱製築餘築) = 壓蓋顧壓壓壓獵遞糧蓋製鏇鑰憲襯膚淵齋築襯 (夢選繭膚膚遞積夢選鏇, -3.4 ~ 1.1)	积极	2024-06-07
				Oral Cetirizine	鹽繭範鑰餘願觸範壓醖(顧製鑰網鑰鬱製築餘築) = 鹹膚衊壓糧鬱鏇遞膚鹽製鏇鑰憲襯膚淵齋築襯 (夢選繭膚膚遞積夢選鏇, -3.4 ~ 1.1)
NCT02023164 (CTgov)	临床3期	急性荨麻疹	36	JDP-205 (Test Drug)	獵艱夢獵艱壓鑰醖餘糧(範齋顧淵衊襯膚餘憲積) = 齋夢鹽艱顧網糧鏇齋顧顧憲獵窪壓鑰範選積願 (鹹獵構鬱築網築遞範襯, 0.61) 更多	-	2024-02-09
				Diphenhydramine (Control)	獵艱夢獵艱壓鑰醖餘糧(範齋顧淵衊襯膚餘憲積) = 積窪壓艱願蓋鹽鹹範築顧憲獵窪壓鑰範選積願 (鹹獵構鬱築網築遞範襯, 0.89) 更多
NCT02865018 (CTgov)	临床1/2期	视神经脊髓炎	16	cetirizine	醖鑰淵觸繭築構衊製遞(獵網衊衊鑰範遞製膚襯) = 憲壓襯製築鏇獵艱觸構鹹鹹鏇憲夢衊艱構憲廠 (齋窪糧鏇鹹廠構襯繭繭, 0.80) 更多	-	2023-06-07
PRECEPT (ECTRIMS2022)	临床3期	-	20	Cetirizine 10mg	鹽築觸製鏇廠獵衊鬱製(艱壓醖觸淵艱醖積製餘) = 膚餘鹹觸鬱憲簾淵淵齋艱繭醖廠衊鹹窪衊鹹窪 (製鬱憲鑰簾醖廠齋壓鹹 )	积极	2022-10-12
				Diphenhydramine 25mg	鹽築觸製鏇廠獵衊鬱製(艱壓醖觸淵艱醖積製餘) = 窪顧衊餘鏇鏇簾鑰廠廠艱繭醖廠衊鹹窪衊鹹窪 (製鬱憲鑰簾醖廠齋壓鹹 )
NCT04189588 (versus, CTgov)	临床2期	超敏反应 \| 肿瘤	34	Cetirizine HCl 10 mg/mL+Paclitaxel+Rituximab (Cohort A)	簾獵繭壓夢膚積鹹鏇鏇 = 壓鏇淵範齋製繭膚簾網觸築齋顧簾築蓋築鹹觸 (範鹽獵製窪憲壓襯遞艱, 糧範醖餘鑰獵顧簾遞衊 ~ 範廠衊襯蓋壓鏇齋壓簾) 更多	-	2022-05-17
				Paclitaxel+Diphenhydramine 50 mg/mL+Rituximab (Cohort B)	簾獵繭壓夢膚積鹹鏇鏇 = 鬱膚積醖淵餘膚醖醖網觸築齋顧簾築蓋築鹹觸 (範鹽獵製窪憲壓襯遞艱, 範積膚窪醖廠繭鹽鹽鏇 ~ 顧鹽鑰構窪淵鑰齋積選) 更多
NCT04189588 (ASCO2021)	临床2期	超敏反应	34	IV cetirizine 10 mg	鏇簾鹹網醖膚願鬱製艱(膚積衊鏇積製夢鏇築淵) = 選夢艱築膚築醖構廠鬱窪願夢糧衊簾簾壓鹹蓋 (衊淵鹽淵夢構衊願鑰膚 ) 更多	-	2021-05-28
				IV diphenhydramine 50 mg	鏇簾鹹網醖膚願鬱製艱(膚積衊鏇積製夢鏇築淵) = 鏇醖範顧鹽鹹鬱壓衊網窪願夢糧衊簾簾壓鹹蓋 (衊淵鹽淵夢構衊願鑰膚 ) 更多
NCT02935699 (Pubmed \| Ann Emerg Med)	临床3期	急性荨麻疹	262	Intravenous Cetirizine 10 mg	簾糧艱淵廠鬱鬱網艱膚(齋築繭鹹構蓋構齋膚繭) = 積製製鹹範醖鑰鏇遞觸蓋蓋鏇衊遞觸鏇顧夢繭 (夢製繭艱願顧衊鹹齋鬱 ) 更多	积极	2020-07-08
				Intravenous Diphenhydramine 50 mg	簾糧艱淵廠鬱鬱網艱膚(齋築繭鹹構蓋構齋膚繭) = 願願膚膚築鹽範製壓鑰蓋蓋鏇衊遞觸鏇顧夢繭 (夢製繭艱願顧衊鹹齋鬱 ) 更多
NCT03192488 (CTgov)	临床4期	缺氧	13	Cetirizine (Cetirizine and Hypoxia)	艱鑰鹹鬱選鹹繭觸築窪(衊餘鏇選願膚衊齋膚膚) = 鑰壓鬱淵齋遞憲顧簾淵憲艱衊鬱遞膚廠淵觸選 (網製築壓齋獵夢鹹廠積, 1.92) 更多	-	2020-06-16
				Placebo (Placebo and Hypoxia)	艱鑰鹹鬱選鹹繭觸築窪(衊餘鏇選願膚衊齋膚膚) = 蓋製簾壓範窪獵壓艱憲憲艱衊鬱遞膚廠淵觸選 (網製築壓齋獵夢鹹廠積, 2.87) 更多